BioCentury
ARTICLE | Product Development

Defining progress

How J&J’s Erleada’s win paves way for new endpoint in early prostate cancer

March 10, 2018 12:54 AM UTC

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before it’s fully advanced.

On Feb. 14, FDA approved the second-generation androgen receptor antagonist from Johnson & Johnson to treat non-metastatic castration-resistant prostate cancer (CRPC) based on the Phase III SPARTAN trial, which used metastasis free survival (MFS) rather than the benchmark overall survival (OS) as the primary endpoint...

BCIQ Target Profiles

Androgen receptor